Hypoglycemic Sensation in Patients Taking Farxiga (Dapagliflozin)
A patient reporting hypoglycemic symptoms while taking dapagliflozin (Farxiga) should have their blood glucose measured immediately, as dapagliflozin alone does not cause true hypoglycemia but symptoms may indicate concurrent use of insulin or sulfonylureas, or represent pseudohypoglycemia from improved glycemic control. 1
Understanding Dapagliflozin and Hypoglycemia Risk
Dapagliflozin is an SGLT-2 inhibitor that works through renal glucose excretion, not by stimulating insulin secretion. The drug itself has minimal intrinsic hypoglycemia risk when used as monotherapy. 2, 3 However, the FDA label explicitly states that when combined with insulin or sulfonylureas, the risk of hypoglycemia increases significantly. 1
Key Clinical Distinctions
The critical first step is to correlate symptoms with actual blood glucose measurements using a glucose meter, not relying on symptoms alone. 4 This is essential because:
- Patients may experience hypoglycemic symptoms at normal glucose levels (pseudohypoglycemia) when transitioning from chronically elevated glucose to better control 4
- Patients may treat perceived hypoglycemia without checking glucose levels 4
- True hypoglycemia requires documented low blood glucose, not just symptoms 5
Immediate Evaluation Protocol
When a patient reports hypoglycemic sensations on dapagliflozin, obtain a fingerstick glucose measurement immediately during symptoms. 5 The evaluation should focus on:
1. Medication Review
- Check if the patient is taking insulin or sulfonylureas concurrently - these are the primary culprits for true hypoglycemia when combined with dapagliflozin 1
- Review total daily insulin dose and timing if applicable 6
- Assess for other glucose-lowering medications 1
2. Glucose Documentation
True hypoglycemia is defined as plasma glucose <70 mg/dL (3.9 mmol/L), with level 2 hypoglycemia at <54 mg/dL (3.0 mmol/L). 4 The FDA label confirms that dapagliflozin monotherapy rarely causes glucose <54 mg/dL. 1
3. Symptom Characterization
- Timing of symptoms relative to meals and medication dosing
- Classic hypoglycemic symptoms: shakiness, sweating, confusion, headache, fast heartbeat, dizziness, hunger 1
- Whether symptoms resolve with carbohydrate intake
- Baseline glucose levels before starting dapagliflozin
Management Algorithm
If True Hypoglycemia is Confirmed (Glucose <70 mg/dL):
Reduce or discontinue the insulin or sulfonylurea dose, not the dapagliflozin. 1 The FDA label specifically states: "The dose of your sulfonylurea medicine or insulin may need to be lowered while you take FARXIGA." 1
- For patients on insulin: Consider reducing basal insulin by 10-20% initially 6
- For patients on sulfonylureas: Consider dose reduction or switching to a medication with lower hypoglycemia risk 1
- Continue dapagliflozin as it provides glycemic benefit without intrinsic hypoglycemia risk 2, 3
If Pseudohypoglycemia (Symptoms with Normal Glucose):
Reassure the patient that symptoms represent adaptation to improved glucose control, not true hypoglycemia. 4 This occurs when:
- Patients have been chronically hyperglycemic and now experience normal glucose levels as "low" 4
- The body's glucose sensing threshold needs recalibration 4
Management approach:
- Educate that symptoms will resolve as the body adapts to better glucose control over 1-2 weeks 4
- Emphasize checking glucose before treating perceived hypoglycemia 4
- Continue current therapy without adjustment 4
If Dapagliflozin Monotherapy:
True hypoglycemia on dapagliflozin alone is extremely rare. 1, 2, 3 In the DECLARE trial involving 8,574 patients, major hypoglycemia occurred less frequently with dapagliflozin versus placebo. 3 If documented:
- Investigate other causes: alcohol use, missed meals, increased physical activity, renal impairment 4
- Screen for impaired hypoglycemia awareness by asking if the patient experiences low glucose without symptoms 4
- Consider other medications or conditions contributing to hypoglycemia 5
Critical Safety Considerations
Assess for Risk Factors
Screen for conditions that increase hypoglycemia risk regardless of medication: 4
- Chronic kidney disease (eGFR <60 mL/min/1.73 m²) - present in 11% of dapagliflozin trial patients 1
- Older age (≥65 years) 4
- Cognitive impairment 4
- Food insecurity 4
Monitor for Ketone Elevation
While evaluating hypoglycemic symptoms, be aware that dapagliflozin can elevate ketone levels without causing hypoglycemia. 7 This is distinct from hypoglycemia but may cause similar malaise. If ketones are elevated (>0.6 mmol/L) without acidosis, this represents euglycemic ketosis, not DKA. 8, 7
Common Pitfalls to Avoid
- Do not discontinue dapagliflozin for hypoglycemic symptoms without first confirming true hypoglycemia and reviewing concurrent medications 1, 2
- Do not rely on patient-reported symptoms alone without glucose measurement - studies show poor correlation between symptoms and actual glucose levels 4
- Do not assume SGLT-2 inhibitors cause hypoglycemia - the mechanism of action (renal glucose excretion) does not stimulate insulin release 2, 9
- Do not ignore the possibility of impaired hypoglycemia awareness - ask specifically about glucose levels at which symptoms occur 4
The key principle: Dapagliflozin's glucose-lowering effect is insulin-independent, making isolated hypoglycemia highly unlikely; investigate concurrent insulin secretagogues or insulin therapy as the primary cause. 1, 2, 3